Table 1 Baseline characteristics (n = 508)
Variables | Total | PNI | SII | NLR | PLR | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
T1 | T3 | P a | T1 | T3 | P a | T1 | T3 | P a | T1 | T3 | P a | ||
Age (IQR)b | 49.0 (43.0– 57.0) | 48.0 (43.5– 55.0) | 50.0 (43.0– 58.0) | 0.970 | 52.0 (44.0. 59.0) | 46.0 (42.0– 51.0) | < 0.001 | 52.0 (45.0– 59.0) | 46.0 (43.0– 52.0) | < 0.001 | 51.0 (44.0– 60.0) | 47.0 (43.0– 52.0) | < 0.001 |
DFS, day (IQR)b | 1393.0 (485.0– 1695.5) | 811.0 (326.0– 1548.5) | 1589.0 (1324.5– 1768.0) | < 0.001 | 1409.0 (484.0– 1671.8) | 1338.0 (419.0– 1673.5) | 0.212 | 1414.0 (548.8– 1679.5) | 1344.0 (419.0– 1677.0) | 0.173 | 1435.5 (637.8– 1723.0) | 1246.0 (427.0– 1585.0) | 0.039 |
OS, day (IQR)b | 1480.0 (689.5– 1728.0) | 1029.0 (340.0– 1614.0) | 1609.0 (1393.5– 1774.5) | < 0.001 | 1483.5 (730.8– 1709.3) | 1397.5 (490.3– 1719.8) | 0.206 | 1476.0 (724.3– 1705.0) | 1454.0 (515.0– 1715.0) | 0.461 | 1510.0 (731.5– 1758.8) | 1383.0 (465.5– 1653.3) | 0.047 |
Family history of BC | 0.070 | 0.715 | 0.814 | 0.543 | |||||||||
No | 367 (72.24) | 117 (23.08) | 129 (25.44) | 120 (23.86) | 123 (24.45) | 126 (24.95) | 119 (23.56) | 124 (24.65) | 119 (23.66) | ||||
Yes | 141 (27.76) | 54 (10.65) | 38 (7.50) | 48 (9.54) | 45 (8.95) | 48 (9.50) | 48 (9.50) | 44 (8.75) | 49 (9.74) | ||||
Body mass index (kg/m2) | 0.675 | 0.326 | 0.341 | 0.114 | |||||||||
18.5–22.9 | 168 (33.07) | 53 (10.45) | 60 (11.83) | 58 (11.53) | 55 (10.93) | 56 (11.09) | 54 (10.69) | 51 (10.14) | 56 (11.13) | ||||
23–27.4 | 236 (46.46) | 79 (15.58) | 82 (16.17) | 73 (14.51) | 74 (14.71) | 82 (16.24) | 76 (15.05) | 84 (16.70) | 68 (13.52) | ||||
≥ 27.5 | 75 (14.76) | 30 (5.92) | 18 (3.55) | 29 (5.77) | 24 (4.77) | 31 (6.14) | 25 (4.95) | 30 (5.96) | 28 (5.57) | ||||
Histological diagnosis | 0.657 | 0.603 | 0.368 | 0.623 | |||||||||
Invasive carcinoma | 452 (88.98) | 151 (29.78) | 150 (29.59) | 146 (29.03) | 149 (29.62) | 150 (29.70) | 149 (29.50) | 150 (29.82) | 153 (30.42) | ||||
Carcinoma in situ | 56 (11.02) | 20 (3.94) | 17 (3.35) | 22 (4.37) | 19 (3.78) | 24 (4.75) | 18 (3.56) | 18 (3.58) | 15 (2.98) | ||||
Clinical stage | 0.848 | 0.787 | 0.878 | 0.757 | |||||||||
0 | 37 (7.28) | 11 (2.17) | 10 (1.97) | 13 (2.47) | 14 (2.75) | 13 (2.47) | 19 (2.61) | 12 (2.34) | 11(2.20) | ||||
I | 107 (20.06) | 34 (6.69) | 35 (6.89) | 39 (7.75) | 36 (7.15) | 35 (6.95) | 33 (6.56) | 33 (6.56) | 39 (7.75) | ||||
II | 263 (51.77) | 92 (18.11) | 89 (17.52) | 87 (17.04) | 89 (17.47) | 92 (18.11) | 81 (17.26) | 93 (18.32) | 79 (15.55) | ||||
III | 100 (19.69) | 32 (6.30) | 35 (6.89) | 32 (6.21) | 25 (4.92) | 35 (6.85) | 28 (5.99) | 33 (6.42) | 35 (6.85) | ||||
IV | 1 (0.20) | 1 (0.20) | 0 (0.00) | 0 (0.00) | 1 (0.10) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (0.11) | ||||
Tumour size, cm | 0.019 | 0.765 | 0.646 | 0.293 | |||||||||
≥ 4 | 391 (76.97) | 123 (24.26) | 139 (27.42) | 136 (27.04) | 133 (26.44) | 141 (27.92) | 127 (25.15) | 128 (25.45) | 136 (27.04) | ||||
< 4 | 79 (15.55) | 35 (2.56) | 19 (1.78) | 23 (4.57) | 20 (3.98) | 22 (4.36) | 23 (4.55) | 29 (5.77) | 22 (4.37) | ||||
Status of ER | 0.329 | 0.632 | 0.421 | 0.657 | |||||||||
Negative | 149 (29.33) | 46 (9.07) | 53 (10.45) | 48 (9.54) | 52 (10.34) | 50 (9.90) | 55 (10.89) | 48 (9.54) | 52 (10.34) | ||||
Positive | 357 (70.28) | 124 (24.46) | 113 (22.29) | 119 (23.66) | 115 (22.86) | 123 (24.36) | 112 (22.18) | 119 (23.66) | 116 (23.06) | ||||
Status of PR | 0.859 | 0.436 | 0.964 | 0.947 | |||||||||
Negative | 203 (39.96) | 68 (13.41) | 68 (13.41) | 68 (13.52) | 61 (12.13) | 68 (13.47) | 66 (13.07) | 66 (13.13) | 67 (13.32) | ||||
Positive | 303 (59.65) | 102 (20.12) | 98 (19.33) | 99 (19.68) | 106 (21.07) | 105 (20.79) | 101 (20.00) | 101 (20.08) | 101 (20.08) | ||||
Status of HER-2 | 0.175 | 0.568 | 0.448 | 0.311 | |||||||||
Negative | 114 (22.44) | 33 (6.51) | 43 (8.48) | 41 (8.15) | 34 (6.76) | 47 (9.31) | 38 (7.52) | 43 (8.55) | 33 (6.56) | ||||
Positive | 347 (68.31) | 122 (24.06) | 109 (21.50) | 116 (23.06) | 113 (22.47) | 115 (22.77) | 112 (22.18) | 113 (22.47) | 115 (22.86) | ||||
Ki67-indexc | 0.186 | 0.229 | 0.122 | 0.827 | |||||||||
≥ 27.5% | 272 (53.54) | 84 (16.57) | 94 (18.54) | 98 (19.48) | 87 (17.30) | 101 (20.00) | 83 (16.44) | 90 (17.89) | 92 (18.29) | ||||
< 27.5% | 236 (46.46) | 87 (17.16) | 73 (14.40) | 70 (13.92) | 81 (16.10) | 73 (14.46) | 77 (16.63) | 78 (15.51) | 76 (15.11) | ||||
Surgical forms | 0.979 | 0.209 | 0.763 | 0.202 | |||||||||
Breast conserving surgery | 61 (12.01) | 20 (3.87) | 21 (4.07) | 17 (3.29) | 26 (5.04) | 24 (4.65) | 23 (4.45) | 16 (3.10) | 26 (5.04) | ||||
Modified radical mastectomy | 249 (49.02) | 80 (15.68) | 83 (16.27) | 82 (16.07) | 72 (14.09) | 91 (17.86) | 76 (14.88) | 89 (17.46) | 82 (16.07) | ||||
Total mastectomy | 190 (37.40) | 70 (13.73) | 61 (11.94) | 68 (13.33) | 66 (12.93) | 59 (11.54) | 65 (12.73) | 63 (12.33) | 56 (10.94) | ||||
Unclear | 8 (1.57) | 3 (0.57) | 3 (0.57) | 2 (0.43) | 4 (0.86) | 1 (0.29) | 4 (0.72) | 1 (0.29) | 4 (0.86) | ||||
Chemotherapy | 0.473 | 0.464 | 0.994 | 0.144 | |||||||||
No | 140 (27.56) | 49 (9.66) | 42 (8.28) | 51 (10.14) | 45 (8.95) | 48 (9.50) | 46 (9.11) | 53 (10.54) | 41 (8.15) | ||||
Yes | 368 (72.44) | 122 (24.06) | 125 (24.65) | 117 (23.26) | 123 (24.45) | 126 (24.95) | 121 (23.96) | 115 (22.86) | 127 (25.25) | ||||
Radiotherapy | 0.570 | 0.635 | 0.714 | 0.343 | |||||||||
No | 355 (69.88) | 119 (23.47) | 121 (23.86) | 118 (23.46) | 114 (22.66) | 123 (24.36) | 115 (22.77) | 120 (23.86) | 112 (22.27) | ||||
Yes | 153 (30.12) | 52 (10.26) | 46 (9.07) | 50 (9.94) | 54 (10.74) | 51 (10.10) | 52 (10.30) | 48 (9.54) | 56 (11.13) | ||||
Endocrine therapy | 0.618 | 0.412 | 0.339 | 0.410 | |||||||||
No | 160 (31.50) | 52 (10.26) | 55 (10.85) | 50 (9.94) | 57 (11.33) | 54 (10.69) | 60 (11.88) | 52 (10.34) | 59 (11.73) | ||||
Yes | 348 (68.50) | 119 (23.47) | 112 (22.09) | 118 (23.46) | 111 (22.07) | 120 (23.76) | 107 (21.19) | 116 (23.06) | 109 (21.67) | ||||
Targeted therapy | 0.380 | 0.566 | 0.758 | 0.848 | |||||||||
No | 462 (90.94) | 155 (30.57) | 156 (30.77) | 149 (29.62) | 152 (30.22) | 161 (31.88) | 153 (30.30) | 153 (30.42) | 154 (30.62) | ||||
Yes | 46 (9.06) | 16 (3.16) | 11 (2.17) | 19 (3.78) | 16 (3.18) | 13 (2.57) | 14 (2.77) | 15 (2.98) | 14 (2.78) | ||||
LNM, clinical | 0.902 | 0.501 | 0.188 | 0.789 | |||||||||
No | 283 (55.71) | 99 (18.15) | 92 (18.15) | 97 (19.28) | 102 (20.28) | 92 (18.22) | 99 (19.60) | 94 (18.69) | 91 (18.09) | ||||
Yes | 223 (43.90) | 77 (15.19) | 75 (14.79) | 71 (14.12) | 64 (12.72) | 82 (16.24) | 66 (13.07) | 74 (14.71) | 76 (15.11) | ||||